期刊文献+

肝门胆管癌的放疗进展 被引量:5

Progress of radiotherapy for hilar cholangiocarcinoma
原文传递
导出
摘要 肝门胆管癌手术切除率及切净率均较低,极大地影响了疗效.放疗作为一种常用的恶性肿瘤治疗方式,对肝门胆管癌的运用有限.近年来随着放疗技术的发展,放疗与肝门胆管癌的研究成为热点.许多研究认为放疗作为手术辅助治疗或保守治疗,可提高肝门胆管癌患者生存期并改善其生存质量. The rate of complete surgical resection is still low in hilar cholangiocarcinoma,which greatly affects the curative effect.Radiotherapy,one kind of treatment for tumors,has not been widely adopted in the past years.In recent years,with the development of radiotherapy technology,research of treating hilar cholangiocarcinoma through radiotherapy has become a spot.Many studies have shown that radiotherapy,as an adjuvant therapy for surgery and non-surgical treatment,can be the major means for treatment,and it could bring benefit for patients' survival extension and improvement of life quality.
出处 《国际肿瘤学杂志》 CAS 2014年第5期350-353,共4页 Journal of International Oncology
基金 国家自然科学基金(81301656)
关键词 胆管肿瘤 放射疗法 预后 Bile duct neoplasms Radiotherapy Prognosis
  • 相关文献

参考文献2

二级参考文献34

  • 1SD Mansfield,O Barakat,RM Charnley,BC Jaques,CB O'Suilleabhain,PJ Atherton,D Manas.Management of hilar cholangiocarcinoma in the North of England: Pathology, treatment, and outcome[J].World Journal of Gastroenterology,2005,11(48):7625-7630. 被引量:37
  • 2Andreas Weber,Sonja Landrock,Jochen Schneider,Manfred Stangl,Bruno Neu,Peter Born,Meinhard Classen,Thomas Rsch,Roland M Schmid,Christian Prinz.Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma[J].World Journal of Gastroenterology,2007,13(9):1422-1426. 被引量:23
  • 3Klatskin G. Adenocarcinoma of the hepatic duct at its bi- furcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 1965; 38:241-256.
  • 4Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215:31-38.
  • 5Inouye AA, Whelan TJ. Carcinoma of the extrahepatic bile ducts: a ten year experience in Hawaii. Am J Surg 1978; 136: 90-95.
  • 6Blumgart LH, Hadjis NS, Benjamin IS, Beazley R. Surgical approaches to cholangiocarcinoma at confluence of hepatic ducts. Lancet 1984; 1:66-70.
  • 7Langer JC, Langer B, Taylor BR, Zeldin R, Cummings B. Carcinoma of the extrahepatic bile ducts: results of an ag- gressive surgical approach. Surgery 1985; 98:752-759.
  • 8Bismuth H, Castaing D, Traynor O. Resection or palliation: priority of surgery in the treatment of hilar cancer. World J Surg 1988; 12:39-47.
  • 9Seyama Y, Kubota K, Sano K, Noie T, Takayama T, Kosuge T, Makuuchi M. Long-term outcome of extended hemihepa- tectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 2003; 238:73-83.
  • 10Valek V, Kysela P, Kala Z, Kiss I, Tomasek J, Petera J. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radio12007; 62:175-179.

共引文献34

同被引文献67

  • 1Emilio Ramos.在 hilar cholangiocarcinoma 的外科的切除术的原则[J].World Journal of Gastrointestinal Oncology,2013,5(7):139-146. 被引量:21
  • 2Lau SH, Lau WY. Current therapy of hilar cholangiocarcinoma [ J ]. Hepatobiliary Pancreat Dis Int,2012, 11 ( 1 ) : 12-17.
  • 3Anaya DA, Blazer DG, Abdalla EK. Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma[ J ]. Semin Intervent Radiol, 2008,25 ( 2 ) : 110-122.
  • 4Nagino M. Perihilar cholangiocarcinoma : a surgeon' s viewpoint on current topics [ J ]. J Gastroenterol, 2012,47 ( 11 ) : 1165-1176.
  • 5Darwish Murad S, Kim WR, Themeau T, et al. Predictors of pre- transplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma [ J ]. Hepatology, 2012, 56 ( 3 ) : 972-981.
  • 6Salgia RJ, Singal AG, Fu S, et al. Improved Post-Transplant Sur- vival in the United States for Patients with CholangiocarcinomaAfter 2000 [ J ]. Dig Dis Sci, 2014,59 (5) : 1048-1054.
  • 7Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoad- juvant chemoradiation, followed by liver transplantation, for pefi- hilar cholangiocarcinoma at 12 US centers [ J ]. Gastroenterology, 2012,143( 1 ) :88-98.
  • 8lto F, Cho CS, Rikkers LF, et al. Hilarcholangiocarcinoma: cur- rent management[J]. Ann Surg, 2009, 250(2): 210-218.
  • 9Mansour JC, Aloia TA, Crane CH, et al. Hilar Cholangiocarcino- ma: expert consensus statement [ J ]. HPB, 2015, 17 ( 8 ) : 691- 699.
  • 10Miyazaki M, Yoshitomi H, Miyakawa S, et al. Clinical practice guidelines fur the management of biliary tract cancers 2015 : the 2nd English edition[J]. J Hepato-Bil Pan Sci, 2015, 22(4): 249- 273.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部